BRIEF-Clearside Biomedical Announces Positive Topline Results From Odyssey Phase 2B Trial Of Suprachoroidal Cls-Ax In Wet AMD Achieving All Primary And Secondary Outcomes

Reuters10-09

Clearside Biomedical Inc :

* CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM ODYSSEY PHASE 2B TRIAL OF SUPRACHOROIDAL CLS-AX IN WET AMD ACHIEVING ALL PRIMARY AND SECONDARY OUTCOMES

* CLEARSIDE BIOMEDICAL INC - ODYSSEY PHASE 2B TRIAL ACHIEVES PRIMARY AND SECONDARY OUTCOMES

* CLEARSIDE BIOMEDICAL INC - CLS-AX SHOWS WELL-TOLERATED SAFETY PROFILE THROUGH WEEK 36

* CLEARSIDE BIOMEDICAL INC - CLS-AX REDUCED TREATMENT BURDEN BY 84% OVER 6 MONTHS

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474938243?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-09 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474938243","market":"us","top_or_hot":-1,"title":"BRIEF-Clearside Biomedical Announces Positive Topline Results From Odyssey Phase 2B Trial Of Suprachoroidal Cls-Ax In Wet AMD Achieving All Primary And Secondary Outcomes","media":"Reuters","content":"<html><body><p>Clearside Biomedical Inc   :</p><p>   * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM ODYSSEY PHASE 2B TRIAL OF SUPRACHOROIDAL CLS-AX IN WET AMD ACHIEVING ALL PRIMARY AND SECONDARY OUTCOMES</p><p>   * CLEARSIDE BIOMEDICAL INC - ODYSSEY PHASE 2B TRIAL ACHIEVES PRIMARY AND SECONDARY OUTCOMES</p><p>   * CLEARSIDE BIOMEDICAL INC - CLS-AX SHOWS WELL-TOLERATED SAFETY PROFILE THROUGH WEEK 36</p><p>   * CLEARSIDE BIOMEDICAL INC - CLS-AX REDUCED TREATMENT BURDEN BY 84% OVER 6 MONTHS</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Clearside Biomedical Announces Positive Topline Results From Odyssey Phase 2B Trial Of Suprachoroidal Cls-Ax In Wet AMD Achieving All Primary And Secondary Outcomes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Clearside Biomedical Announces Positive Topline Results From Odyssey Phase 2B Trial Of Suprachoroidal Cls-Ax In Wet AMD Achieving All Primary And Secondary Outcomes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-09 19:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clearside Biomedical Inc   :   * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM ODYSSEY PHASE 2B TRIAL OF SUPRACHOROIDAL CLS-AX IN WET AMD ACHIEVING ALL PRIMARY AND SECONDARY OUTCOMES   ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1852331112.SGD","symbol_name":"Blackrock World Technology Fund A2 SGD-H","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2474938243","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474938243","pubTimestamp":1728471943,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Clearside Biomedical Inc   :   * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM ODYSSEY PHASE 2B TRIAL OF SUPRACHOROIDAL CLS-AX IN WET AMD ACHIEVING ALL PRIMARY AND SECONDARY OUTCOMES   * CLEARSIDE BIOMEDICAL INC - ODYSSEY PHASE 2B TRIAL ACHIEVES PRIMARY AND SECONDARY OUTCOMES   * CLEARSIDE BIOMEDICAL INC - CLS-AX SHOWS WELL-TOLERATED SAFETY PROFILE THROUGH WEEK 36   * CLEARSIDE BIOMEDICAL INC - CLS-AX REDUCED TREATMENT BURDEN BY 84% OVER 6 MONTHSSource text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","BK4566":"资本集团","BK4575":"芯片概念","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","BK4007":"制药","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","CLSD":"Clearside Biomedical Inc.","LU1316542783.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","BK4141":"半导体产品","BK4588":"碎股","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","LU2250418816.HKD":"BGF WORLD TECHNOLOGY \"A\" (HKD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","GFS":"GLOBALFOUNDRIES Inc.","LU0642271901.SGD":"Janus Henderson Horizon Global Technology Leaders A2 SGD-H","BK4573":"虚拟现实","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","LU0082616367.USD":"摩根大通美国科技A（dist）","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","LU0056508442.USD":"贝莱德世界科技基金A2","LU0823421333.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","BK4512":"苹果概念","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","LU0823421416.USD":"BNP PARIBAS DISRUPTIVE TECHNOLOGY \"C\" (USD) INC","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU0081259029.USD":"UBS (LUX) EQUITY FUND - TECH OPPORTUNITY \"P\" (USD) ACC","LU0109392836.USD":"富兰克林科技股A","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","BK4529":"IDC概念","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC"},"translate_title":"简介-Clearside Biomedical宣布脉络膜上腔Cls-Ax治疗湿性AMD的ODYSSEY 2b期试验取得积极的顶线结果，实现了所有主要和次要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLSD":1,"GFS":1},"content_text":"Clearside Biomedical Inc   :   * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM ODYSSEY PHASE 2B TRIAL OF SUPRACHOROIDAL CLS-AX IN WET AMD ACHIEVING ALL PRIMARY AND SECONDARY OUTCOMES   * CLEARSIDE BIOMEDICAL INC - ODYSSEY PHASE 2B TRIAL ACHIEVES PRIMARY AND SECONDARY OUTCOMES   * CLEARSIDE BIOMEDICAL INC - CLS-AX SHOWS WELL-TOLERATED SAFETY PROFILE THROUGH WEEK 36   * CLEARSIDE BIOMEDICAL INC - CLS-AX REDUCED TREATMENT BURDEN BY 84% OVER 6 MONTHSSource text for Eikon:    Further company coverage:","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474938243"}